CRABP1-CaMKII-Agrn regulates the maintenance of neuromuscular junction in spinal motor neuron.
Yu-Lung LinJennifer NhieuPei-Yao LiuGengyun LeDong Jun LeeChin-Wen WeiYi-Wei LinSang-Hyun OhDawn LoweLi-Na WeiPublished in: Cell death and differentiation (2022)
Cellular retinoic acid-binding protein 1 (CRABP1) binds retinoic acid (RA) specifically in the cytoplasm with unclear functions. CRABP1 is highly and specifically expressed in spinal motor neurons (MNs). Clinical and pre-clinical data reveal a potential link between CRABP1 and MN diseases, including the amyotrophic lateral sclerosis (ALS). We established a sequenced MN-muscle co-differentiation system to engineer an in vitro functional 3D NMJ model for molecular studies and demonstrated that CRABP1 in MNs contributes to NMJ formation and maintenance. Consistently, Crabp1 knockout (CKO) mice exhibited an adult-onset ALS-like phenotype with progressively deteriorated NMJs, characterized with behavioral, EchoMRI, electrophysiological, histological, and immunohistochemical studies at 2-20-months old. Mechanistically, CRABP1 suppresses CaMKII activation to regulate neural Agrn expression and downstream muscle LRP4-MuSK signaling, thereby maintaining NMJ. A proof-of-concept was provided by specific re-expression of CRABP1 to rescue Agrn expression and the phenotype. This study identifies CRABP1-CaMKII-Agrn signaling as a physiological pre-synaptic regulator in the NMJ. This study also highlights a potential protective role of CRABP1 in the progression of NMJ deficits in MN diseases.
Keyphrases
- amyotrophic lateral sclerosis
- binding protein
- poor prognosis
- spinal cord
- rheumatoid arthritis
- skeletal muscle
- genome wide
- gene expression
- traumatic brain injury
- type diabetes
- signaling pathway
- long non coding rna
- machine learning
- systemic lupus erythematosus
- disease activity
- big data
- human health
- insulin resistance
- risk assessment
- ankylosing spondylitis
- systemic sclerosis
- wild type